Syncona Limited (SYNC) · 2026-06-18

Final Results

Syncona reported FY results with net assets of £1,037.7m and NAV per share of 170.6p. Shareholders approved a new policy focused on returning at least £250m, while Beacon Therapeutics helped drive portfolio value after its Series C financing.

Syncona Limited (SYNC) · 2026-06-17

Directorate change

Syncona has appointed Norman Crighton as an independent non-executive director from 1 July 2026. The board move comes as it works on its new Investment Policy and returning at least £250 million to shareholders.